Receptor for Advanced Glycosylated End Products C-terminal Antiserum
The Receptor for Advanced
Glycosylated End Products (RAGE) is a member of the immunoglobulin superfamily of cell
surface proteins that binds molecules that have been irreversibly
modified by non-enzymatic glycation and oxidation. They are known as
advanced glycation end products (AGEs).
It is expressed by endothelium, mononuclear phagocytes, neurons and
smooth muscle cells. Whereas
RAGE is present at high levels during development, especially in the
central nervous system, its levels decline during maturity.
The increased expression of RAGE is associated with
several pathological states, such as diabetic vasculopathy,
retinopathy and neuropathy, and other disorders, including Alzheimer’s
disease and immune/inflammatory reactions of the vessel walls. In diabetic tissues, the production of RAGE is due to the
overproduction of AGEs that eventually overwhelm the protective properties
of RAGE. This results in
oxidative stress and endothelial cell dysfunction that leads to vascular
disease in diabetics. In the
brain, RAGE also binds amyloid beta (Ab).
is overproduced in neurons and vessels in the brains of Alzheimer disease,
this leads to the hyperstimulation of RAGE.
The RAGE-Ab interaction is thought to result in oxidative stress
leading to neuronal degeneration.
A goat antiserum to a synthetic peptide that corresponds to amino acids 385-399 of the C-terminus of human RAGE protein is currently available. This antiserum has been shown to be immunoreactive with the unconjugated immunizing peptide by ELISA. It will also immunolabel AGE from diabetic tissues in formalin-fixed, paraffin-embedded tissues. This antibody should be a valuable tool for scientists working to understand the role of RAGE in diabetes and AD.
This antiserum was produced using proprietary methodology whereby the peptide is attached to a carrier that elicits minimal immunoreactivity so that the antiserum has a higher degree of specificity for the peptide. Since there is no overwhelming production of interfering antibodies to the carrier, this antiserum can routinely be used without further purification. Pseud-Immune™ control immune serum (Cat no. GPA018E) from a mock immunized animal is available to be used in conjunction with this antibody as well as the immunizing peptide (Cat no. HSP032C), which can be used to neutralize immunoreactivity.
Southwest Immunology, Inc., unpublished results.
|Form:||Whole Serum - liquid|
|Supplied as:||1 ml vials or bulk quantities|
Reported working dilution using neat serum:*
*Various assay conditions require that the optimum working concentrations be determined by serial dilutions of this product.
|Specificity:||C-terminal amino acid sequence 385-399 of human Receptor for Advanced Glycosylated End Products protein.|
|0.1% Sodium Azide|
|Storage:||Short term: Refrigerate at 4˚ C|
|Long term: Freeze at -20˚ C|
FOR RESEARCH AND MANUFACTURING USE ONLY.
N/D = Not determined.
[Home ] [Company] [New Products] [Protocols] [Contact Us]